Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roivant Sciences Ltd
(NQ:
ROIV
)
10.90
-0.04 (-0.37%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,837,387
Open
10.93
Bid (Size)
10.75 (3)
Ask (Size)
11.00 (10)
Prev. Close
10.94
Today's Range
10.79 - 11.05
52wk Range
8.060 - 13.24
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
April 22, 2024
Via
Benzinga
Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study
April 02, 2024
Roivant Sciences and Priovant Therapeutics report Phase 2 results for brepocitinib in treating non-anterior non-infectious uveitis. Week 24 data show promising efficacy, with lower treatment failure...
Via
Benzinga
Performance
YTD
-3.96%
-3.96%
1 Month
+9.55%
+9.55%
3 Month
+4.31%
+4.31%
6 Month
+25.00%
+25.00%
1 Year
+22.89%
+22.89%
More News
Read More
Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study
April 02, 2024
Via
Investor's Business Daily
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
April 02, 2024
From
Roivant Sciences
Via
GlobeNewswire
Where Roivant Sciences Stands With Analysts
March 25, 2024
Via
Benzinga
The Analyst Landscape: 4 Takes On Roivant Sciences
February 14, 2024
Via
Benzinga
Roivant Sciences Earnings Preview
February 12, 2024
Via
Benzinga
Assessing Roivant Sciences: Insights From 5 Financial Analysts
January 02, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
March 29, 2024
Via
Benzinga
Solar Stocks Rally, Led By Sunrun, SolarEdge, Enphase
March 27, 2024
Via
Investor's Business Daily
5 Value Stocks In The Healthcare Sector
February 19, 2024
Via
Benzinga
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
February 13, 2024
From
Roivant Sciences
Via
GlobeNewswire
Analyst Ratings for Roivant Sciences
December 12, 2023
Via
Benzinga
8 Analysts Have This to Say About Roivant Sciences
November 14, 2023
Via
Benzinga
Earnings Scheduled For February 13, 2024
February 13, 2024
Via
Benzinga
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
January 30, 2024
From
Roivant Sciences
Via
GlobeNewswire
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
January 12, 2024
Via
Investor's Business Daily
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
January 10, 2024
Via
Benzinga
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
December 21, 2023
Via
Benzinga
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
December 20, 2023
From
Roivant Sciences
Via
GlobeNewswire
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
December 20, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
December 14, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
November 28, 2023
From
Roivant Sciences
Via
GlobeNewswire
Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today?
November 27, 2023
Via
Benzinga
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
November 27, 2023
From
Roivant Sciences
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.